New Gene Therapy Restores Vision in Patients with Inherited Blindness

A revolutionary gene therapy treatment has successfully restored functional vision in 28 out of 30 patients suffering from Leber congenital amaurosis, a rare inherited condition that causes progressive blindness beginning in early childhood. The results, published in the New England Journal of Medicine, represent one of the most dramatic therapeutic successes in the history of gene therapy.

The treatment, developed by gene therapy pioneer Dr. Katherine Sterling and her team at the Wilmer Eye Institute at Johns Hopkins University, involves a single injection of a modified adeno-associated virus carrying a corrected copy of the RPE65 gene directly into the retina of each eye. The procedure takes approximately 45 minutes per eye and is performed under local anesthesia.

Patients in the trial ranged in age from 4 to 44 years old, all diagnosed with the RPE65 mutation that prevents the retina from producing a protein essential for converting light into electrical signals that the brain can interpret as vision. Prior to treatment, most patients could perceive only bright light or large objects at close range.

"The improvement has been life-changing for these patients," Dr. Sterling said. "Within weeks of treatment, patients who had never seen their children's faces were able to do so for the first time. Patients who could not navigate independently began walking through unfamiliar environments without assistance."

Objective testing confirmed the dramatic improvements reported by patients. Visual acuity improved by an average of 15 lines on a standard eye chart, with some patients achieving near-normal vision. Perhaps more importantly, patients demonstrated significant improvements in their ability to navigate obstacle courses under varying light conditions, a functional measure that directly relates to real-world independence.

Eight-year-old Maria Gonzalez, one of the youngest participants in the trial, described her experience through tears shared with her parents. "I can see the colors of flowers now," she said at a press conference organized by Johns Hopkins. "And I can see my mommy's smile." Her mother, Elena Gonzalez, called the treatment "a miracle we had stopped hoping for."

The therapy builds on earlier work that earned a Nobel Prize for the development of adeno-associated virus vectors for gene therapy. While a previous gene therapy for the same condition received FDA approval in 2017, it required retreatment in many patients and showed diminishing effectiveness over time. The new treatment uses an improved viral vector and delivery method that appears to produce more durable results.

Follow-up data extending to three years after treatment shows sustained visual improvement in all responding patients, with no evidence of the therapeutic effect diminishing over time. Side effects were minimal, with the most common being temporary mild inflammation at the injection site that resolved within two weeks. The research team is now planning trials for additional genetic forms of blindness and is exploring whether similar approaches could benefit patients with age-related macular degeneration, the leading cause of vision loss in older adults worldwide. Regulatory approval applications are expected to be filed within the next six months.